Axovant Sciences Ltd. (NYSE:AXON) Sees Unusual Volume Mid-Session

According to their observations and findings, the stock could provide a high EPS of $-0.37/share and a Low EPS of $-0.62/share.

Axovant Sciences Ltd. (AXON) stock price distance from twenty day simple moving average surged at 25.00% while its distance from fifty day simple moving average raised 37.79% along with 34.78% above distance from two hundred simple moving averages.

Axovant shares ripped 30% higher Monday morning. Today, shares climbed another 10% after the company announced it's shoring up its balance sheet with a $100 million stock offering. For the Current Quarter, 5 analysts are projecting the mean EPS to be $-0.5/share.

Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Tuesday, February 14th. For the next year, analysts anticipate that the business will report earnings of ($2.08) per share, with EPS estimates ranging from ($2.47) to ($1.76).

Several research analysts have recently issued reports on AXON shares.

The stock added in the prior trading session by 9.22%, closing at the stock price of $20.25.

12/20/2016 - Laidlaw began new coverage on Axovant Sciences giving the company a "sell" rating. They set an outperform rating and a $22.00 price target on the stock. Zacks Investment Research downgraded shares of Axovant Sciences from a "hold" rating to a "sell" rating in a report on Tuesday, February 7th.

Current levels places Axovant Sciences Ltd. (NYSE:AXON)'s stock about -1.06% from the 50-day high and 87.10% away from the 50-day low. The company had a trading volume of 5,267,758 shares. The total market capitalization remained at $2.46 billion. The company has a 50-day moving average of $14.10 and a 200 day moving average of $13.30. Wells Fargo & Company MN now owns 8,130 shares of the company's stock worth $113,000 after buying an additional 117 shares during the period. Opus Point Partners Management LLC boosted its position in shares of Axovant Sciences by 10.9% in the third quarter. Opus Point Partners Management LLC now owns 14,844 shares of the company's stock valued at $208,000 after buying an additional 1,455 shares during the period. Norges Bank purchased a new position in shares of Axovant Sciences during the fourth quarter worth $508,000. Deltec Asset Management LLC now owns 75,000 shares of the company's stock worth $1,050,000 after buying an additional 64,500 shares during the last quarter. Inc. increased its stake in shares of Axovant Sciences by 0.5% in the third quarter.

Axovant Sciences is maintaining its momentum following the appointment of star biotech leader David Hung earlier this week with a new $125 million share offering.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of USA and global copyright and trademark law.

06/07/2016 - Leerink Swann began new coverage on Axovant Sciences giving the company a "outperform" rating.

Also in the company's pipeline is nelotanserin an inverse agonist of the 5HT2A receptor being developed to treat neuropsychiatric disturbances including visual hallucinations, which are a common occurrence in people living with Lewy body dementia.

  • Todd Kelly